In Replay Of Avandia Ban, Saudi Arabia First Regulator To Withdraw Long-acting Beta Agonists As Sole Therapy
This article was originally published in PharmAsia News
Executive Summary
The Saudi Arabia Food and Drug Authority appears to be the first regulatory agency to announce a withdrawal of long acting beta agonists that are not combined with corticosteroids, citing evidence of a linkage to an increased risk of death from asthma-related complications